You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

Details for Patent: 9,511,039


✉ Email this page to a colleague

« Back to Dashboard


Title:Enterically coated cysteamine, cystamine and derivatives thereof
Abstract: The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.
Inventor(s): Dohil; Ranjan (San Diego, CA), Schneider; Jerry (La Jolla, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Filing Date:Nov 24, 2015
Application Number:14/950,234
Claims:1. A method of administering cystamine, or pharmaceutically acceptable salts thereof, to a patient in need thereof comprising administering to said patient a pharmaceutical composition comprising cystamine, or pharmaceutically acceptable salts thereof, wherein the composition increases delivery of cystamine, or pharmaceutically acceptable salts thereof, to the small intestine and wherein the frequency of administering is less than four times daily.

2. The method of claim 1, wherein each dose of cystamine is about 0.5-1.0g/m.sup.2 body surface area.

3. The method of claim 1, wherein the total daily dose of cystamine is about 1.35 g/m.sup.2 body surface area or less.

4. The method of claim 1, wherein the composition comprises enterically coated cystamine or a salt thereof.

5. The method of claim 4, wherein each dose of cystamine is about 0.5-1.0 g/m.sup.2 body surface area.

6. The method of claim 4, wherein the total daily dose of cystamine is about 1.35 g/m.sup.2 body surface area or less.

7. The method of claim 4, wherein the composition comprises a coating selected from the group consisting of polymerized gelatin, shellac, methacrylic acid copolymer type CNF, cellulose butyrate phthalate, cellulose hydrogen phthalate, cellulose proprionate phthalate, polyvinyl acetate phthalate (PVAP), cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT), hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate, dioxypropyl methylcellulose succinate, carboxymethyl ethylcellulose (CMEC), hydroxypropyl methylcellulose acetate succinate (HPMCAS), and acrylic acid polymers and copolymers formed from methyl acrylate, ethyl acrylate, methyl methacrylate and/or ethyl methacrylate with copolymers of acrylic and methacrylic acid esters.

8. The method of claim 1, wherein the pharmaceutical composition comprises a capsule containing enterically coated cystamine granules, wherein the enteric coating allows dissolution during the approximate 3 hour transit time in the small intestine and begins dissolution in the duodenum and continues to dissolve through the mid-small intestine.

9. A method of administering cystamine or a pharmaceutically acceptable salt thereof to a patient with cystinosis, comprising administering to said patient a pharmaceutical composition comprising cystamine or a pharmaceutically acceptable salt thereof, twice per day, wherein the composition increases delivery of cystamine or the pharmaceutically acceptable salt thereof to the small intestine.

10. The method of claim 9, wherein each dose of cystamine is about 0.5-1.0 g/m.sup.2 body surface area.

11. The method of claim 9, wherein the total daily dose of cystamine is about 1.35 g/m.sup.2 body surface area or less.

12. The method of claim 9, wherein the composition comprises enterically coated cystamine or a salt thereof.

13. The method of claim 12, wherein each dose of cystamine is about 0.5-1.0 g/m.sup.2 body surface area.

14. The method of claim 12, wherein the total daily dose of cystamine is about 1.35 g/m.sup.2 body surface area or less.

15. The method of claim 12, wherein the composition comprises a coating selected from the group consisting of polymerized gelatin, shellac, methacrylic acid copolymer type CNF, cellulose butyrate phthalate, cellulose hydrogen phthalate, cellulose proprionate phthalate, polyvinyl acetate phthalate (PVAP), cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT), hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate, dioxypropyl methylcellulose succinate, carboxymethyl ethylcellulose (CMEC), hydroxypropyl methylcellulose acetate succinate (HPMCAS), and acrylic acid polymers and copolymers formed from methyl acrylate, ethyl acrylate, methyl methacrylate and/or ethyl methacrylate with copolymers of acrylic and methacrylic acid esters.

16. The method of claim 9, wherein the pharmaceutical composition comprises a capsule containing enterically coated cystamine granules, wherein the enteric coating allows dissolution during the approximate 3 hour transit time in the small intestine and begins dissolution in the duodenum and continues to dissolve through the mid-small intestine.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.